



Substitute for Form 1449A/PTD				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/689,235		
				Filing Date	October 20, 2003		
				First Name Inventor	Dermatakis, et al.		
Sheet	1	of	1	Attorney Docket Number	21269 US1		
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
42	A1	6,150,373		Harris, et al.	11/21/2000		
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁴
		Office ³	Number ³	Kind Code ³ (if known)			
K	B1		WO 03/062236		Warner Lambert Co. LLC	07/31/2003	
	B2		WO 98/24432		Sugen, Inc.	06/11/1998	
	B3		WO 99/61444		Warner Lambert Co.	12/02/1999	
	B4		WO 01/29041		F.Hoffmann-La Roche AG	04/26/2001	
	B5		WO 01/29042		F.Hoffmann-La Roche AG	04/26/2001	
	B6		WO 01/64679		Smithkline Beecham Corp.	09/07/2001	
NON PATENT LITERATURE DOCUMENTS							
d	C1	Hennequin L. F. et al., J. Med. Chem. 2002, Vol. 45(6) pgs. 1300-1312					
	C2	Klohs W. E. et al., Current Opinion in Biotechnology, 1999 Vol. 10, pgs. 544-549					
	C3	D. H. Boschelli & F. Boschelli, Drugs of the Future, 2000 25(7) pgs. 717-736					
Examiner Signature							

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation or abstract is attached.

137909



Substitute for Form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/689,235		
(Use several sheets if necessary)				Filing Date	October 20, 2003		
				First Name Inventor	Dermatakis, et al.		
Sheet	1	of	2	Attorney Docket Number	21269 US1		
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
J	A2	2,949,466		Hoefle, et al.	08/16/1960		
	A3	4,886,807		Kitamura, et al.	12/12/1989		
	A4	3,939,084		Sullivan	02/17/1976		
	A5	4,425,346		Horlington	01/10/1984		
	A6	6,451,804		Dunn, et al.	09/17/2002		
	FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
u	B3	WO 02/18380 A1			F.Hoffmann-La Roche AG	03/07/2002	
NON PATENT LITERATURE DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					T ²
J	C3	Ansel, H. et al., <i>Pharmaceutical Dosage Forms & Drug Delivery Systems</i> 6 th Ed. 1995, pg. 196					
	C4	J. Alexander, et al., <i>J. Med. Chem.</i> 1988, Vol. 31, pgs. 318-322					
	C5	Masquelin et al., <i>Helvetica Chimica Acta</i> , Vol. 81 (1998) pgs. 646-659					
	C6	Devi, et al., <i>Indian Journal of Heterocyclic Chemistry</i> , Vol. 7, January - March, 1998, pgs. 193-196					
	C7	Tominaga et al., <i>Chemical & Pharmaceutical Bulletin</i> , Vol. 32, No. 1, January 1984, pgs. 122-129					
	C8	Tominaga et al., <i>Heterocycles</i> , Vol. 12, No. 4. 1979, pgs. 503-504					
	C9	Marsh et al., <i>Chemical Communications</i> , 1996, pgs. 1527-1528					
	C10	<i>Z. Chem.</i> 20 Jg (1980) Heft. 11, pgs. 412-413					
	C11	Cappuccino et al., <i>Cancer Research</i> , Vol. 24, August 1964, pgs. 1243-1248					
	C12	Chatterjee et al., <i>J. Sci. Industr. Res.</i> , Vol. 17B, February, 1958, pgs. 63-70					
	C13	Chatterjee et al., <i>J. Sci. Industr. Res.</i> , Vol. 18B, July, 1959, pgs. 272-278					
	C14	Graboyes et al., <i>Pteridines X.</i> , Vol. 11 January 6, 1968, pgs. 568-573					
	C15	Grohe et al., <i>Liebigs Ann. Chem.</i> , 1974, pgs. 2066-2073					

Tom McLepe 8/21/05



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/689,235
				Filing Date	October 20, 2003
				First Name Inventor	Dermataakis, et al.
Sheet	2	of	2	Attorney Docket Number	21269 US1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
✓	C16	Gulevskaya et al., <i>Chemistry of Heterocyclic Compounds</i> , Vol. 30, No. 9, 1994, pgs. 1083-1091	
	C17	Hirota et al., <i>J. Chem. Soc. Perkin Trans. 1</i> , 1990, pgs. 123-128	
	C18	Srivastava, et al., <i>Combinatorial Chemistry & High Throughout Screening</i> , 1999, 2, pgs. 33-37	
	C19	Taylor et al., <i>Pyrimido [4,5-D]Pyrimidines</i> , Vol. 82, pgs. 5711-5718	
	C20	Wamhoff et al., <i>Heterocycles</i> , Vol. 35, No. 2, 1993, pgs. 1055-1066	
	C21	M. Hirota et al., "A Facile Synthesis of 7-Substituted Pyrimido[4,5-d]-Pyrimidine-2,4-diones", <i>Synthesis</i> , pgs. 589-590 (1984)	
Examiner Signature	Dan McKe		Date Considered 8/31/02

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation or abstract is attached.

138508

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.1). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstracts is attached.

Substitution for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT 12 2004 (Use several sheets if necessary)			Complete if Known	
			Application Number	10/689,235
			Filing Date	October 20, 2003
			First Name Inventor	Dermataakis, et al.
			Group Art Unit	
			Examiner Name	
Sheet 1	of	1	Attorney Docket Number	21269 US1

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
J	B7		WO 00 24744		F.Hoffmann-La Roche AG	05-04-2000	
Examiner Signature		Date Considered					

* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

